Reference
1. Gu C, Wu Y, Luo Y, et al. Real-world efficacy and safety of dupilumab
in Chinese patients with atopic dermatitis: a single-centre,
prospective, open-label study. J Eur Acad Dermatol Venereol . Jul
2022;36(7):1064-1073. doi:10.1111/jdv.18109
2. Zhou B, Peng C, Li L, et al. Efficacy and Safety of Dupilumab in
Chinese Patients With Atopic Dermatitis: A Real-World Study. Front
Med (Lausanne) . 2022;9:838030. doi:10.3389/fmed.2022.838030
3. Song X, Liu B, Luan T, et al. Moderate-to-severe atopic dermatitis in
different age groups treated with dupilumab in China. Allergy .
Jan 27 2023;doi:10.1111/all.15660
4. Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children
aged 6 months to younger than 6 years with uncontrolled atopic
dermatitis: a randomised, double-blind, placebo-controlled, phase 3
trial. Lancet . Sep 17 2022;400(10356):908-919.
doi:10.1016/s0140-6736(22)01539-2
5. Cheng J, Jiang L, Morrow NC, et al. Recognition of atopic
keratoconjunctivitis during treatment with dupilumab for atopic
dermatitis. J Am Acad Dermatol . Jul 2021;85(1):265-267.
doi:10.1016/j.jaad.2020.09.046
6. Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of
dupilumab with concomitant topical corticosteroids in children 6 to
11 years old with severe atopic dermatitis: A randomized,
double-blinded, placebo-controlled phase 3 trial. J Am Acad
Dermatol . Nov 2020;83(5):1282-1293. doi:10.1016/j.jaad.2020.06.054